Merck KGaA broke ground in early 2020 on the $275 Biotech Development Center in Corsier-sur-Vevey, Switzerland. Constructed adjacent to the company's existing commercial manufacturing campus, the 169,000-sf project will provide advanced research, development, and production facilities to support the creation of innovative biological compounds for clinical studies. Collocating approximately 250 employees currently sited at disparate locations, the building will leverage advanced digital technologies, fully automated laboratories, and flexible infrastructure to accelerate the delivery of next-generation therapeutics. Offering collaborative open workspaces, the sustainably designed structure will feature abundant natural light, highly efficient infrastructure, and an architectural design that preserves the site's biodiversity. Completion is expected in 2021 with operations commencing in late 2022.
